These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12437272)

  • 1. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers.
    Davies R; Crabbe D; Roderick P; Goddard JR; Raftery J; Patel P
    Health Care Manag Sci; 2002 Nov; 5(4):249-58. PubMed ID: 12437272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
    Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
    J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.
    Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Bhandari P; Patel P
    Health Technol Assess; 2003; 7(6):1-86. PubMed ID: 12709294
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
    Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Yokota K; Oguma K
    J Gastroenterol; 2007 Jan; 42 Suppl 17():21-7. PubMed ID: 17238021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
    Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
    Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
    Høgh MB; Kronborg C; Hansen JM; Schaffalitzky de Muckadell OB
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1013-1025. PubMed ID: 30854700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori public health implications.
    Moayyedi P; Hunt RH
    Helicobacter; 2004; 9 Suppl 1():67-72. PubMed ID: 15347308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we screen for Helicobacter pylori to prevent gastric cancer?
    Leja M; Dumitrascu DL
    Dig Dis; 2007; 25(3):218-21. PubMed ID: 17827943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration.
    Schulz TR; McBryde ES; Leder K; Biggs BA
    PLoS One; 2014; 9(9):e108610. PubMed ID: 25268809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Helicobacter pylori: screen and treat?].
    Malfertheiner P
    Dtsch Med Wochenschr; 2014 May; 139(17):905-8. PubMed ID: 24760696
    [TBL] [